Chronic Lymphocytic Leukemia Therapeutics Market

SKU: DMPH1792 | Last Updated On: Sep 21 2022 | Available Formats

>Chronic Lymphocytic Leukemia Therapeutics Market Expected to reach a high CAGR of 7.90% by 2029:

Chronic Lymphocytic Leukemia Therapeutics Market is segmented By Cancer Type (B-cell chronic lymphocytic leukemia, T-cell chronic lymphocytic leukemia, Natural killer chronic lymphocytic leukemia), By Drug Type (Chemotherapy Drugs, Immuno and Targeted Drugs(Venetoclax, Ibrutinib, Obinutuzumab, Duvelisib, and others)), By Route (Intravenous route, Oral Route and others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

 

Chronic Lymphocytic Leukemia Therapeutics Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.90% during the forecast period (2022-2029).

Chronic Lymphocytic Leukemia Therapeutics Market Scope

Metrics

Details

Market CAGR

7.90%

Segments Covered

By Cancer Type, By Drug Type, By Route of Administration, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy marked by excessive proliferation of abnormal white blood cells. CLL predominantly affects the B-cell lymphocytes involved in producing antibodies to fight against infections and foreign antigens. Chronic lymphocytic leukemia symptoms include swollen lymph nodes, fever, exhaustion, abdominal pain from an enlarged spleen, weight loss, night sweats, repeated infections, and others.

Market Dynamics

Increasing FDA approvals for treating Chronic Lymphocytic Leukemia is expected to drive market growth.

The Food and Drug Administration (FDA) of the United States authorized Imbruvica (ibrutinib) in conjunction with rituximab on April 21, 2020, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This is the 11th FDA approval for Imbruvica (ibrutinib) since it was approved in 2013 and the sixth in CLL, the most common form of adult leukemia. Moreover, On November 9, 2020, the European Medical Agency (EMA), the European Union for treating adult patients with chronic lymphocytic leukemia (CLL). Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Stringent government regulations, inadequate reimbursement policies in emerging countries, and multiple patent expiration are the factors the market is expected to hamper the market growth.

Industry Analysis

The chronic lymphocytic leukemia therapeutics market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis, epidemiology etc.

Segment Analysis

Targeted Therapy segment is expected to hold the largest market share in the chronic lymphocytic leukemia therapeutics market.

The targeted therapy segment accounted for the largest market share in 2021. Targeted therapies are drugs that specifically target the changes inside cells that cause them to become cancer. Unlike standard chemotherapy drugs, which work by attacking rapidly growing cells in general (including cancer cells), these drugs target one or more specific proteins on or in chronic lymphocytic leukemia (CLL) cells. When treatment is needed for CLL, a targeted drug is often part of the first line of treatment. Targeted therapies use information about a person’s genes and protein to prevent, diagnose, and treat disease, making them extremely applicable in precision medicine. Targeted therapy drugs are mainly used for cancer treatment, along with other treatments such as chemotherapy, surgery, and radiation therapy. The targeted cancer therapies market is growing due to the increasing incidences of chronic lymphocytic leukemia (CLL). For instance, according to the report published by the American Cancer Society in January 2020, the risk of CLL increases with age, and it estimates that about 9 out of 10 people with CLL are over age 50, directly driving for growth of the CLL market. The major types of targeted drugs most commonly used to treat CLL include Rituximab (Rituxan), Ofatumumab (Arzerra), Obinutuzumab (Gazyva), Venetoclax (Venclexta), Ibrutinib (Imbruvica) and Idelalisib (Zydelig). Therefore, it has increased the demand for targeted therapy. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period. ​

Geographical Analysis

North American region is expected to hold the largest market share in the global chronic lymphocytic leukemia therapeutics market.

North America accounted for the largest market share in 2021. The rising incidence of CLL coupled with a high mortality rate demonstrates the unmet market need for better therapeutics. For instance, according to cancer.net, in 2021, 21,250 people of all ages (13,040 men and boys and 8,210 women and girls) in the United States will be diagnosed with CLL. While it can occur at any age, CLL is more common in older adults. The average age at diagnosis is around 70. CLL is uncommon in people younger than 40 and is very rare in children. CLL is the most common type of leukemia in adults older than 19, accounting for 38% of all leukemia diagnoses. The rate of new cases of chronic lymphocytic leukemia was 4.9 per 100,000 men and women per year. Therefore, National Health Federation in the United States has been awarding grants and fellowships to support innovative research to find better treatments and cures for several bleeding disorders. Such research has led to vital insights into improved factor replacement therapies, along with more accurate chronic lymphocytic leukemia therapeutics methods and, therefore, definitely a greater understanding of the genetic basis of the disease. Hence, the rising prevalence of the disease and the growing initiatives by several organizations are driving market growth in the region.

Moreover, an increase in the approvals from regulatory bodies and ongoing research activities by the major companies in the United States are likely to contribute the largest share of revenue in the region, propelling the global chronic lymphocytic leukemia market. For instance, in November 2019, AstraZeneca PLC received US Food and Drug Administration (FDA) approval for its Calquence (acalabrutinib) to treat adult patients with CLL, which is expected to impel the global Chronic lymphocytic leukemia market growth. Furthermore, few key players are entering into partnerships to develop and increase their market position globally. Thus, rising awareness campaigns and supportive initiatives planned by the government to commence early screening of neonates are expected to boost the market for chronic lymphocytic leukemia therapeutics in the region.

Competitive Landscape

Major key players in the chronic lymphocytic leukemia therapeutics market are GlaxoSmithKline Plc, AbbVie Inc., Biogen Idec, AstraZeneca, Genentech Inc., MorphoSys AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Portola Pharmaceuticals, Inc, Celgene Corporation.

MorphoSys AG:

Overview:

MorphoSys AG is a biopharmaceutical company headquartered near Munich, Germany. The company has a wholly-owned subsidiary, MorphoSys US Inc., in Boston, MA, in the US. The company has various antibody, protein and peptide technologies to discover and develop proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are investigated for various diseases. Moreover, the company also has a pipeline focusing on cancer and autoimmune diseases. The company develops its drugs in partnership with pharma and biotech companies. 

Product Portfolio: 

Monjuvi(R)(tafasitamab-cxix): It is also known as MOR208, is a humanized monoclonal antibody precision medicine directed against the CD19 antigen, which is expressed on early B lymphocytes and B cell lymphomas which makes it a potential target for the treatment of non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma, as well as chronic lymphocytic leukemia (CLL).

The global chronic lymphocytic leukemia therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages

Frequently Asked Questions

What is the Projected CAGR value of the Chronic Lymphocytic Leukemia Therapeutics Market?

Chronic Lymphocytic Leukemia Therapeutics Market is expected to grow at a CAGR of 7.90% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Chronic Lymphocytic Leukemia Therapeutics Market during 2022-2029

Which is the fastest growing region in the Chronic Lymphocytic Leukemia Therapeutics Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

Acute Myeloid Leukaemia Therapeutics Market

Acute Lymphocytic Leukemia Therapeutics Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest